Reprogramming Neutrophils to Combat Bone Cancer: A Breakthrough in Immunotherapy

Strategic Insights -

Researchers from the Ludwig Institute for Cancer Research have discovered a key mechanism behind the resistance of bone tumors to immunotherapy. By repolarizing neutrophils, a type of frontline immune cell, cancer researchers have found a potential way to improve the efficacy of immunotherapy treatments for bone tumors. The study, led by Taha Merghoub and Tao Shi, reveals that the protein DKK1 reprograms neutrophils into an immature state, suppressing anti-tumor immune responses. By blocking DKK1, researchers were able to restore the sensitivity of bone metastases to cancer immunotherapy in mouse models.

Key Takeaways:

  • DKK1 reprograms neutrophils into a functionally immature state, suppressing anti-tumor immune responses.
  • The study suggests that DKK1-blockade could be used as a combination treatment to improve the efficacy of immune checkpoint blockade therapies against bone tumors.
  • Neutrophils play a critical role in the tumor microenvironment, and targeting and reprogramming these cells may provide a new avenue for cancer therapy.
  • CHI3L3, a molecule produced by immature neutrophils, disrupts the activation and function of cytotoxic T cells.
  • The researchers identified a biochemical signaling cascade activated by DKK1 that reprograms neutrophils, revealing potential drug targets to disrupt the process.
  • Blocking DKK1 in mice with bone metastases of triple-negative breast cancer led to mature neutrophils that no longer suppressed cytotoxic T cell function, allowing bone tumors to shrink and immune checkpoint blockade therapy to work effectively.
  • The findings suggest that DKK1-blockade could be used in combination with immune checkpoint blockade therapies to combat bone tumors, for which there are no currently effective therapies.
  • DKK1-blocking antibodies are already in clinical trials, which could hasten progress in translating these findings into patient care.
  • The study highlights the importance of targeting and reprogramming innate immune cells like neutrophils for cancer therapy.

Statistics:

  • Bone metastases are often resistant to immunotherapy, with no currently effective therapies available.
  • Neutrophils play a complex and highly mutable role in cancer, depending on their functional states.
  • The study found that immature neutrophils induced by DKK1 suppress cytotoxic T cell function and create a profoundly immunosuppressive tumor microenvironment.
  • The researchers identified that a DKK1-blocking antibody (DKN-01) is already in clinical trials, which could significantly hasten progress in translating these findings into patient care.
  • The study was supported by multiple organizations, including the Ludwig Institute for Cancer Research, the Breast Cancer Research Foundation, and the National Science and Technology Major Program.

Sources:

  • Ludwig Institute for Cancer Research
  • Swim Across America
  • The Breast Cancer Research Foundation
  • The Parker Institute for Cancer Immunotherapy
  • The National Natural Science Foundation of China
  • The National Key Research and Development Program of China
  • The China Postdoctoral Science Foundation
  • Jiangsu Provincial Medical Key Discipline
  • The Funding of the Major Program of Shenzhen Bay Laboratory
  • National Science and Technology Major Program
  • The Fundamental Research Funds for the Central Universities
  • The Jiangsu Provincial Science and Technology Plan Special Fund